





CLINICAL TRIALS OPEN TO ACCRUAL

Questions? Please contact the UC Cancer Institute Clinical Trials Office at 513-584-7698, or cancer@uchealth.com

Protocol No.	Protocol Title	Contacts
Phase I		
 MS201964-0001 2018-7823	A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors	PI: John Morris Coordinator: Bethany Fuhrman; fuhrmaba@uc.edu
AST-008-012 NCT03684785 IRB 2019-0158	A Phase I b/2 Study of AST-008 Combined with Pembrolizumab in Patients with Advanced Solid Tumors	PI: Trisha Wise-Draper Coordinator: Sheena Chandler; chandlsm@uc.edu
EMR200647-001 NCT02517398 IRB 2015-9180	A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications	PI: John Morris Coordinator: Sheena Chandler; chandlsm@uc.edu
D6070C00001 NCT02503774 IRB 2017-3044	A Phase I Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with durvalumab in Adult Subjects with Select Advanced Solid Tumors	PI: Trisha Wise-Draper Coordinator: Sheena Chandler; chandlsm@uc.edu
3000-01-002 NCT03307785 IRB 2018-6839	Phase I b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination with TSR-042 in Patients with Advanced or Metastatic Cancer	PI: Muhammad Riaz Coordinator: Sheena Chandler; chandlsm@uc.edu
3000-01-004 NCT03329001 IRB 2018-7238	An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients with Advanced Solid Tumors.	PI: Trisha Wise-Draper Coordinator: Sheena Chandler; chandlsm@uc.edu
BBI-DSP7888-102CI NCT03311334 IRB 2018-1225	A Phase I b, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Atezolizumab in Adult Subjects with Advanced Solid Tumors	PI: Trisha Wise-Draper Coordinator: Sheena Chandler; chandlsm@uc.edu
H3B-6527-G000-101 NCT02834780 IRB 2016-8364	An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma	PI: John Morris Coordinator: Sheena Chandler; chandlsm@uc.edu
Brain		
EAF151 NCT03115333 IRB 2018-1020	Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma	PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu

IRB 2017-2183	Feasibility Study of Hypofractionated Radiotherapy in the Setting of Recurrent Diffuse Intrinsic Pontine Glioma	PI: Luke Pater Coordinator: Hope Esslinger; Hope.Esslinger@uchealth.com
CG01-GBM NCT03632135 IRB 2018-	Phase II Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma	PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu
NRG-BN003 NCT03180268 IRB 2018-0118	Phase II Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma	Sub-I: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu
A071401 NCT02523014 IRB 2016-1035	TEMP CLOSED- Phase II trial of smo/akt/nf2 inhibitors in progressive meningiomas with smo/akt/nf2 mutations	PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu
CAE3313 NCT01894061 IRB 2013-7226	A Prospective Phase II Trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with Recurrent Glioblastoma	PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu
NRG-BN001 NCT02179086 IRB 2014-8049	Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temzolomide in Patients with Newly Diagnosed Glioblastoma	Sub-I: Luke Pater Coordinator: Max Mays; maysmw@uc.edu
UCCI-BN-16-01 NCT03122197 IRB 2016-8917	A Phase 0/I Exploratory Pharmacokinetic and Pharmacodynamics Study of Letrozole in Combination with Standard Therapy in Recurrent Gliomas.	PI: Trisha Wise-Draper Coordinator: Max Mays; maysmw@uc.edu
UCCI-BRAIN-16-01 NCT03278249 IRB 2017-0956	Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma	PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu
Breast		
 EA1131 2019-0644	A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy	PI: Neetu Radhakrishnan Coordinator: Laura Bundus; bundusla@uc.edu
 D5336C00001 (VIOLETTE) 2018-6242	A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)	PI: Neetu Radhakrishnan Coordinator: Laura Bundus; bundusla@uc.edu
Daiichi Sankyo DS8201-A-U301 IRB 2018-4169	A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201A, an Anti-HER2-Antibody Drug Conjugate, versus Treatment of Investigator's Choice for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated with Prior Standard of Care HER2 Therapies, including T-DM1	PI: Mahmoud Charif Coordinator: Laura Bundus; bundusla@uc.edu
3510 NCT02603341 IRB 2017-1626	Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial	PI: Teresa Meier Coordinator: Laura Bundus; bundusla@uc.edu
EA1151- TMIST NCT03233191 IRB 2018-2735	Tomosynthesis Mammographic Imaging Screening Trial (TMIST)	PI: Lawrence Sobel Coordinator: Monene Kamm; kammmm@ucmail.uc.edu

VVA-Laser	This is a randomized trial to determine the comparative effectiveness of the CO2RE laser device relative to topical lidocaine in treating dyspareunia among breast cancer survivors.	PI: James Whiteside Coordinator: Mollie Mosley; moselyme@ucmail.uc.edu
A221505 NCT03414970 IRB 2018-1652	Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction	PI: Teresa Meier Coordinator: Laura Bundus; bundusla@uc.edu
A011401 NCT02750826 IRB 2018-0248	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer	PI: Neetu Radhakrishnan Coordinator: Laura Bundus; bundusla@uc.edu
B-51/RTOG1304 NCT01872975 IRB 2013-3979	A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post -Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes after Neoadjuvant Chemotherapy	Sub-I: Teresa Meier Coordinator: Laura Bundus; bundusla@uc.edu
Gastrointestinal		
NRG-GI003 NCT03186898 IRB 2018-1655	A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma	PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu
SWOG S1815 IRB 2019-0578	A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers	PI: Olugbenga Olowokure Coordinator: Patti Rose; Rosepi@uc.edu
D6070C00005 NCT03611556 IRB 2018-2641	A Phase Ib/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma	PI: Olugbenga Olowokure Coordinator: Patti Rose; Rosepi@uc.edu
NRG-GI004 NCT02997228 IRB 2018-1656	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atexolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer	PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu
EA2165 NCT03233711 IRB 2018-4036	A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer	PI: Tahir Latif Coordinator: Patti Rose; Rosepi@uc.edu
19244 NCT03289273 IRB 2018-0965	REFINE: Regorafenib observational study in hepatocellular carcinoma	PI: Olugbenga Olowokure Coordinator: Patti Rose; Rosepi@uc.edu
NRG-GI006 IRB 2019-0567	Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment Of Esophageal Cancer	PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu
NRG-GI003 NCT03186898 IRB 2018-1655	A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma	PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu
EA2142 NCT02595424 IRB 2017-7106	Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas	PI: Olugbenga Olowokure Coordinator: Patti Rose; Rosepi@uc.edu

UCCI-GI-16-01 NCT03018418 IRB 2016-5763	A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer	PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu
Genitourinary		
SWOG S1802 IRB 2019-0309	Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer	PI: Abhinav Sidana Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu
EOVIST IRB 2016-4426	Gadoxetate Sodium Enhanced Magnetic Resonance Imaging (MRI) as a Biomarker for Aggressive Prostate Cancer	PI: Sadhna Verma Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu
NRG-GU006 NCT03371719 IRB 2018-6243	A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer.	PI: Jordan Kharofa Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu
IRB 2017-1091 NCT03564275	University of Cincinnati Proton Boost for Prostate Cancer Utilizing MR Imaging	PI: William Barrett Coordinator: Hope Esslinger; Hope.Esslinger@uchealth.com
EA8143 NCT03055013 IRB 2017-4426	A Phase III RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	PI: John Morris Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu
Gyn Onc		
 2017C0128 OPTEC 2019-0544	Ohio Prevention and Treatment of Endometrial Cancer (OPTEC)	PI: Caroline Billingsley Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu
Bio-Data-16-01	Using Novel Objective Bio-data to Improve Quality of Life Assessment in Patients Undergoing Cytotoxic Chemotherapy: An Interventional Pilot Study III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu
NRG-GY005 NCT02502266	A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)	PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu
NRG-GY006 NCT02466971	A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal	PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu
GOG0238 NCT00492778	A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus	PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu
GOG0263 NCT01101451	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy	PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu
Head and Neck		
ISA101b-HN-01-17 NCT03258008 IRB 2018-4826	A Randomized, Double-blind, Placebo-Controlled, Phase II Study of Cemiplimab Versus the Combination of Cemipilimab with ISA101b in the Treatment of Subjects with HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)	PI: Muhammad Riaz Coordinator: Aubrey Steele; steleab@uc.edu

XL184-311 NCT03690388 IRB 2018-6366	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer who have progressed after Prior VEGFR-Targeted Therapy.	PI: David Steward Coordinator: Aubrey Steele; steeleab@uc.edu
EA3163 NCT03493425 IRB 2018-5130	Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)	PI: Vinita Takiar Coordinator: Aubrey Steele; steeleab@uc.edu
UCCI-HN-17-02 NCT03691714 IRB 2018-0252	An open-label, phase II study of Durvalumab (MEDI4736) in combination with Cetuximab in previously treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)	PI: Trisha Wise-Draper Coordinator: Aubrey Steele; steeleab@uc.edu
NRG-HN004 NCT03258554 IRB 2018-0254	Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin	Sub-I: Vinita Takiar Coordinator: Aubrey Steele; steeleab@uc.edu
NRG-HN001 NCT02135042 IRB 2014-4045	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	Sub-I: Vinita Takiar Coordinator: Aubrey Steele; steeleab@uc.edu
RTOG 1008 NCT01220583 IRB 2012-4268	A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors	Sub-I: Vinita Takiar Coordinator: Aubrey Steele; steeleab@uc.edu
UCCI-HN-15-01 NCT02641093 IRB 2015-6798	Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC	PI: Trisha Wise-Draper Coordinator: Aubrey Steele; steeleab@uc.edu
CDX3379-04 NCT03254927 IRB 2018-0968	A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination with Cetuximab in Patients with Advanced Head and Neck Squamous Cell Carcinoma	PI: Trisha Wise-Draper Coordinator: Aubrey Steele; steeleab@uc.edu
UCCI-HN-17-01/CA209-997 NCT03355560 IRB 2017-2824	A Single Arm Phase II Study of Adjuvant Nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy	PI: Trisha Wise-Draper Coordinator: Aubrey Steele; steeleab@uc.edu
Hematology (Benign and Malignant)		
AML003 NCT03504410 IRB 2018-7758	Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)	PI: Zartash Gul Coordinator: Michelle Nguyen; nguyenmt@uc.edu
BL-8040-SCM-301 NCT03246529 IRB 2018-1226	A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multicentre Study Evaluating The Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects with Multiple Myeloma - The Genesis Study	PI: Tahir Latif Coordinator: Michelle Nguyen; nguyenmt@uc.edu
UCCI-HEM-17-01 NCT03688451 IRB 2017-5730	Feasibility and safety of Intrathecal Rituximab added to standard Intrathecal prophylaxis to prevent CNS relapse for CD 20 positive Non Hodgkin Lymphoma	PI: Tahir Latif Coordinator: Michelle Nguyen; nguyenmt@uc.edu

2017-1 NCT03394755 IRB 2017-5650	A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts	PI: Jose Cancelas Coordinator: Michelle Nguyen; nguyenmt@uc.edu
Lung		
A151216 NCT02194738 IRB 2015-0131	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)	PI: John Morris Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu
A081105 NCT02193282 IRB 2015-0135	Randomized study of erlotinib vs observation in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLS)	PI: John Morris: Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu
E4512 NCT02201992 IRB 2015-0134	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein	PI: John Morris Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu
EA5142 NCT02595944 IRB 2016-6078	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers	PI: John Morris Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu
NRG-LU002 NCT03137771 IRB 2018-0251	Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial	Sub-I: Kevin Redmond Coordinator: Lauren Hendricks; hendrilu@uc.edu
BPI-2358-103 NCT02504489 IRB 2015-4653	Randomized Phase III Assessment of Second Line Treatment with Docetaxel + Plinabulin Compared to Docetaxel alone in Patients with Advanced Non-Small Cell Lung Cancer with at Least 1 Large Lung Lesion	PI: John Morris Coordinator: Lauren Hendricks; hendrilu@uc.edu
CALGB30610 NCT00632853 IRB 2013-2796	Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide	PI: Kevin Redmond Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu
MS200095-0022 NCT02864992 IRB 2016-6074	A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen	PI: John Morris Coordinator: Lauren Hendricks; hendrilu@uc.edu
STU022015-069 NCT02468024 IRB 2015-6789	A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SABR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)	PI: Sandra Starnes Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu
RRX001-211-01 NCT02489903 IRB 2017-2426	A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens	PI: John Morris Coordinator: Lauren Hendricks; hendrilu@uc.edu
Skin		
EA6174 NCT03712605 IRB 2019-0337	A Phase III Randomized Trial of Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma	PI: Rekha Chaudhary Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu

<p>S1801 NCT03698019 IRB 2019-0311</p>	<p>A Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma</p>	<p>PI: Rekha Chaudhary Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu</p>
<p>2125-MEL-301 NCT03445533 IRB 2018-1638</p>	<p>A Randomized Phase III Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory melanoma</p>	<p>PI: Rekha Chaudhary Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu</p>